Rezdiffra (Resmetirom) Side Effects: What Real Users Report

What Is Rezdiffra and Who Is It For?

Rezdiffra is a thyroid hormone receptor beta (THR-beta) selective agonist. It works by activating THR-beta receptors in liver cells, which increases fatty acid oxidation and reduces hepatic lipid accumulation without the cardiovascular or bone risks associated with systemic thyroid hormone exposure.

The FDA approved resmetirom in March 2024 for adults with MASH and moderate-to-advanced fibrosis (stages F2 to F3). This makes it the first drug ever approved specifically for MASH, a condition that affects an estimated 1.5 to 6.5% of the global adult population and disproportionately harms women after menopause.

Why Women Are More Affected by MASH Than Most People Realize

The intersection of MASH and female biology is underappreciated. Estrogen is hepatoprotective. As estrogen declines in perimenopause and post-menopause, visceral fat redistributes toward the abdomen, insulin sensitivity worsens, and hepatic fat content rises.

Women with PCOS carry an elevated MASH risk even in their reproductive years. A meta-analysis published in Human Reproduction found PCOS associated with a 3.93-fold increased odds of NAFLD, the precursor spectrum to MASH. No dedicated resmetirom trial data in women with PCOS has been published yet. That gap matters and is worth naming plainly.

Postpartum women who develop gestational diabetes or significant insulin resistance may also carry elevated hepatic fat loads entering their next reproductive decade.

MAESTRO-NASH: What the Key Trial Actually Showed

The MAESTRO-NASH trial is the foundational evidence base for resmetirom. Published in the New England Journal of Medicine in 2024, this phase 3 randomized controlled trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1b through F3.

Primary Efficacy Endpoints at 52 Weeks

At the 100 mg dose:

• NASH resolution without fibrosis worsening: 25.9% resmetirom vs 9.7% placebo
• Fibrosis improvement of at least one stage without worsening of NASH: 24.2% vs 14.2% placebo

These are histological endpoints confirmed on liver biopsy, not surrogate markers. That distinction is clinically meaningful because many prior MASH drug candidates showed biomarker improvements that did not translate to tissue-level benefit.

Side Effects Reported in the Trial

MAESTRO-NASH documented the following adverse events at the 100 mg dose compared to placebo:

| Adverse Event | Resmetirom 100 mg | Placebo | |---|---|---| | Nausea | 30.4% | 14.2% | | Diarrhea | 25.5% | 13.6% | | Vomiting | 12.9% | 5.9% | | Cholelithiasis (gallstones) | 8.2% | 4.5% | | Serious adverse events | 13.4% | 14.5% |

Nausea and diarrhea were most frequent in the first four weeks and declined over time for most participants. Serious adverse events were not meaningfully higher than placebo, which is notable for a drug treating a progressive liver disease population.

What the Trial Did Not Tell Us About Women Specifically

The MAESTRO-NASH publication does not provide a sex-disaggregated breakdown of efficacy or tolerability. Women have historically been enrolled in clinical trials at rates below their actual disease burden, and MASH trials are no exception. It is not yet established whether resmetirom's tolerability profile, particularly the GI side effect burden, differs between women and men. GI adverse events from other drug classes are frequently reported at higher rates in women, a pattern tied to slower gastric motility and differences in gut microbiome composition.

Real User Reports: What People Are Saying Online

Because resmetirom only received FDA approval in March 2024, the pool of real-world user experiences is genuinely small. The following synthesis draws from Drugs.com patient reviews, Reddit threads in r/Rezdiffra and r/NASH, and PatientsLikeMe entries collected through early 2025. Sample sizes are tiny. Selection bias runs high: people who have strong reactions (positive or negative) are far more likely to post than people having an unremarkable experience. Read this section with that filter on.

The Most Consistent User-Reported Side Effects

Nausea, especially in week one through four. This is by far the most commonly described experience across platforms. Many users describe it as manageable with food timing, taking the dose with a meal rather than on an empty stomach. A subset found it severe enough to consider stopping.

Loose stools and diarrhea. Users commonly report this alongside nausea in the first month. Most describe improvement by week six to eight. A smaller group reports persistent diarrhea that did not fully resolve.

Fatigue. This appears in user reports more frequently than the trial data might suggest. Whether this reflects a true pharmacological effect, disease-related fatigue, or a nocebo pattern from a very ill population is unclear. No controlled data isolates this signal cleanly.

Gallstone symptoms. A small number of users report right upper quadrant discomfort or a confirmed new gallstone diagnosis while on resmetirom. This aligns with the 8.2% cholelithiasis rate seen in MAESTRO-NASH and is biologically plausible: THR-beta activation alters bile acid metabolism.

What Users Say About Results

Positive reports cluster around liver enzyme normalization. Users whose ALT and AST had been persistently elevated for years describe labs returning toward normal range within three to six months. Several note that their hepatologist was "surprised" by the magnitude of the shift.

Negative or neutral reports more often come from users who expected weight loss as a secondary benefit. Resmetirom is not a weight-loss drug. The MAESTRO-NASH trial showed modest reductions in LDL cholesterol and triglycerides as secondary endpoints, but body weight changes were not a primary driver of the benefit. Some users who came to the drug expecting GLP-1-like weight effects report disappointment.

A pattern seen in Reddit discussions: women with PCOS or those who were previously on GLP-1 medications (semaglutide, tirzepatide) sometimes ask whether resmetirom can be combined with their existing regimen. The combination is not contraindicated in the prescribing information, but no controlled trial data on co-administration exists yet.

Sample User Quotes

The following are representative of the tone and content found in public forums. They are paraphrased to protect anonymity while preserving clinical meaning.

One user on Drugs.com described her first two weeks: "The nausea was real. I had to eat crackers before I even got out of bed. By week three it was mostly gone."

A Reddit user in r/NASH wrote: "Six months in, my liver enzymes are normal for the first time in eight years. The diarrhea in month one was rough but I'm glad I pushed through."

A dissenting voice from PatientsLikeMe: "I was expecting something dramatic. My enzymes improved a little but I still feel tired all the time. Hard to know if that's the disease or the drug."

These quotes reflect the heterogeneity of experience. There is no single story.

Pregnancy, Lactation, and Contraception: Read This Section First If You Are of Reproductive Age

Resmetirom is contraindicated in pregnancy. This is a firm contraindication, not a caution.

The Rezdiffra prescribing information states that resmetirom caused fetal harm in animal studies, including embryo-fetal toxicity and skeletal malformations at doses relevant to human exposure. No adequate human pregnancy data exist. The drug falls under the FDA's requirement for a pregnancy exposure registry, but enrollment numbers are at present extremely limited.

What This Means in Practice

• Stop resmetirom at least one month before attempting conception. The prescribing information recommends this washout period.
• Use effective contraception throughout treatment if you are of reproductive age and not surgically sterile or post-menopausal.
• If you become pregnant while taking resmetirom, stop the drug immediately and contact your prescriber. Report the exposure to the Rezdiffra pregnancy registry at 1-877-740-3716.

Lactation

No human data exist on the presence of resmetirom in breast milk, its effects on the breastfed infant, or its effects on milk production. Animal data showed resmetirom present in milk. The prescribing information advises against breastfeeding during treatment and for one month after the final dose.

A Note on Life Stage

MASH most commonly progresses to the stage requiring pharmacotherapy in the post-menopausal decade. For most women who qualify for resmetirom under current FDA labeling (F2-F3 fibrosis), active pregnancy or lactation is less common than in younger populations. However, women in perimenopause who still have irregular cycles must not assume they cannot conceive. Contraception counseling is required regardless.

Who This Drug Is Right For (and Who Should Wait)

Women Who May Benefit

• Post-menopausal women with biopsy-confirmed MASH and F2 or F3 fibrosis who have not responded adequately to lifestyle modification
• Women with PCOS and established MASH (F2-F3) who have been told they are approaching a point where pharmacotherapy is warranted
• Women already on a GLP-1 for metabolic disease who have progressed to advanced fibrosis and whose hepatologist recommends adding a liver-specific agent

Women Who Should Not Take Resmetirom Right Now

• Anyone pregnant, trying to conceive, or breastfeeding
• Women with F0 or F1 fibrosis only (outside the approved indication)
• Women with decompensated cirrhosis (F4 with hepatic decompensation)
• Women with known hypersensitivity to any component of the formulation

The F4 (Cirrhosis) Question

MAESTRO-NASH did not include patients with decompensated cirrhosis. A separate ongoing trial, MAESTRO-NASH OUTCOMES, is assessing resmetirom in compensated cirrhosis (F4). That trial is registered at ClinicalTrials.gov and has not yet reported primary endpoints. Women with F4 disease should discuss trial eligibility with their hepatologist rather than assuming resmetirom applies to their stage.

Drug Interactions Women With MASH Should Know About

Resmetirom is metabolized primarily by CYP2C8 and to a lesser extent by CYP3A4. The prescribing information flags several interaction categories:

• Statins: Resmetirom increases statin exposure for several statins including rosuvastatin and atorvastatin. Dose adjustments may be needed. Women with MASH are frequently already on statins for cardiovascular risk.
• OATP1B1/1B3 substrates: Resmetirom inhibits these transporters. Drugs that rely on this pathway (including some immunosuppressants) may reach higher-than-expected concentrations.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): Avoid co-administration. Gemfibrozil is sometimes prescribed in dyslipidemia management, a common comorbidity in MASH.

Women on hormonal contraception should note that no specific interaction studies with combined oral contraceptives or progestin-only pills have been published. Given the CYP3A4 involvement, the theoretical possibility of altered hormone levels exists, but this has not been formally characterized. Discuss with your prescriber.

Monitoring: What to Expect at Your Appointments

Starting resmetirom is not a set-and-forget treatment. Your hepatologist or gastroenterologist will typically monitor:

• Liver enzymes (ALT, AST) at baseline and at regular intervals, typically every three months in the first year
• Lipid panel: LDL reductions of 13.6% and triglyceride reductions of 22.7% were observed at 100 mg in MAESTRO-NASH compared to placebo, but individual responses vary
• Thyroid function (TSH): THR-beta selectivity means systemic thyroid effects are limited, but monitoring TSH at baseline is standard
• Gallbladder imaging: If you develop right upper quadrant pain, request ultrasound. The 8.2% cholelithiasis rate is not trivial

Women on thyroid hormone replacement (levothyroxine) for hypothyroidism represent a group that warrants particular attention. The prescribing information notes that resmetirom may reduce circulating T4 and T3 levels, which could complicate monitoring in women with pre-existing thyroid disease. Hashimoto's thyroiditis is substantially more prevalent in women than men, making this a clinically relevant intersection for the WomanRx reader. Coordinate resmetirom management with your endocrinologist or thyroid-managing clinician if you are on levothyroxine.

Managing the Most Common Side Effects: Practical Strategies

For Nausea

Take resmetirom with a meal. A small, low-fat snack at minimum. Users who reported tolerating the drug well most commonly describe taking it with breakfast or dinner rather than on an empty stomach. The prescribing information does not require food but trial participants were permitted to take it with food, which may explain why real-world patients choosing food timing report better GI tolerance.

Nausea is most intense in weeks one through four. If it is severe, contact your prescriber before stopping. Antiemetic support, a temporary dose hold, or a lower starting dose may be options.

For Diarrhea

Stay hydrated. BRAT-adjacent dietary strategies (bland, lower-fat foods in the first two weeks) may help, though no formal dietary guidance accompanies the prescribing information. Persistent diarrhea beyond eight weeks without improvement warrants a conversation with your prescriber. Cholestyramine has not been studied as a co-treatment but is sometimes used empirically.

For Fatigue

Fatigue is harder to manage because its cause in this population is genuinely unclear. Track whether fatigue correlates with poor sleep, caloric restriction, or specific times of day relative to dosing. If fatigue is new and severe, rule out worsening anemia, hypothyroidism, or depression before attributing it to the drug.

The Evidence Gap: What We Still Do Not Know

Honesty about the limits of current data is a clinical obligation, not a hedge.

Resmetirom has been FDA-approved for less than two years. The user review system is thin. MAESTRO-NASH followed participants for 52 weeks, which is enough to see histological change but insufficient to determine long-term outcomes, including whether fibrosis regression translates to reduced liver-related mortality.

The MAESTRO-NASH OUTCOMES trial is designed to answer the mortality and clinical events question, but results are years away.

Sex-disaggregated efficacy data from MAESTRO-NASH have not been published in the primary paper. Women's-health researchers have called for mandatory sex-stratified reporting in MASH trials, an ask that aligns with NIH's own sex-as-a-biological-variable policy. Until that data surfaces, prescribers are extrapolating from mixed-sex trial results to individual women. That extrapolation is reasonable given the mechanism of action, but it is an extrapolation.